Preventing disease: One billion pigs vaccinated with Ingelvac CircoFLEX^®

Ingelheim, Germany, 14 February 2013 - Veterinarians and farmers across the globe have reached the landmark of protecting one billion pigs from the potentially devastating effects of Porcine Circovirus Disease (PCVD) using Ingelvac CircoFLEX^®. The vaccine, which was launched by Boehringer Ingelheim Animal Health in 2006, contributes to securing the pigs’ health as well as providing healthier pork for people to consume around the world.

Based on yearly sales volumes (in comparison to all other vaccines in animal health)*1, Ingelvac CircoFLEX^® is the most successful animal vaccine of all time. The efficacy and safety of Ingelvac CircoFLEX^®, which is a unique combination of Purified Circo Antigen (PCA^®) and the adjuvant platform ImpranFLEX^®,  have established the brand globally as customers’ number one choice for vaccinating pigs against PCVD for several years*2.

PCVD is considered as being one of the most costly swine diseases – both from a herd health and an economic perspective. Prevention of PCVD and other diseases through vaccination reduces the need for antibiotics and leads to an improved quality of food for consumers worldwide.

References

1. Based on local and international market research data (data on file).

2. Local and international market research data 2008 - 2011; for 2012 based on Q1 – Q3.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information please visit www.boehringer-ingelheim.com